<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5338">
  <stage>Registered</stage>
  <submitdate>21/08/2015</submitdate>
  <approvaldate>21/08/2015</approvaldate>
  <nctid>NCT02593851</nctid>
  <trial_identification>
    <studytitle>A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection</studytitle>
    <scientifictitle>A Phase 1b, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With RSV Infection</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2015-002003-28</secondaryid>
    <secondaryid>CR107945</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Respiratory Syncytial Virus Infections</healthcondition>
    <healthcondition>Virus Diseases</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Sexually transmitted infections</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - JNJ-53718678
Treatment: drugs - Placebo

Experimental: Part 1: Cohort 1a - Participants (greater than or equal to [&gt;=] 6 months and less than or equal to [&lt;=] 24 months of age) will receive JNJ-53718678, 2 milligram per kilogram body weight (mg/kg) oral solution once daily on Day 1 to Day 7. Dose and/or dosing regimen may be adapted in subsequent cohorts based on the review of the safety/tolerability and full pharmacokinetic data from Cohort 1a.

Experimental: Part 1: Cohort 1b - Participants (&gt;= 6 months and &lt;= 24 months of age) will receive total daily dose of 6 mg/kg JNJ-53718678 oral solution or placebo [either in once daily [qd] or twice daily [bid]) on Day 1 to Day 7.

Experimental: Part 1: Cohort 1c - Participants (&gt;= 6 months and &lt;= 24 months of age) will receive total daily dose of 18 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.

Experimental: Part 1: Cohort 1d - Participants (&gt;= 6 months and &lt;= 24 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 1d is optional and may be included at the discretion of the sponsor.

Experimental: Part 1: Cohort 1e - Participants (&gt;= 6 months and &lt;= 24 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 1e is optional and may be included at the discretion of the sponsor.

Experimental: Part 1: Cohort 2a - Participants (&gt;= 3 months and less than [&lt;] 6 months of age) will receive total daily dose of 1.5 mg/kg JNJ-53718678 oral solution [either in a qd or a bid regimen] on Day 1 to Day 7.

Experimental: Part 1: Cohort 2b - Participants (&gt;=3 months and &lt; 6 months of age) will receive total daily dose of 4.5 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.

Experimental: Part 1: Cohort 2c - Participants (&gt;= 3 months and &lt; 6 months of age) will receive total daily dose of 13.5 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7

Experimental: Part 1: Cohort 2d - Participants (&gt;= 3 months and &lt; 6 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 2d is optional and may be included at the discretion of the sponsor.

Experimental: Part 1: Cohort 2e - Participants (&gt;= 3 months and &lt; 6 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 2e is optional and may be included at the discretion of the sponsor.

Experimental: Part 1: Cohort 3a - Participants (greater than (&gt;) 1 month and &lt; 3 months of age) will receive total daily dose of 1 mg/kg JNJ-53718678 oral solution [either in a qd or a bid regimen] on Day 1 to Day 7.

Experimental: Part 1: Cohort 3b - Participants (&gt; 1 month and &lt; 3 months of age) will receive total daily dose of 3 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.

Experimental: Part 1: Cohort 3c - Participants (&gt; 1 month and &lt; 3 months of age) will receive total daily dose of 9 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.

Experimental: Part 1: Cohort 3d - Participants (&gt; 1 month and &lt; 3 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 3d is optional and may be included at the discretion of the sponsor.

Experimental: Part 1: Cohort 3e - Participants (&gt; 1 month and &lt; 3 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 3e is optional and may be included at the discretion of the sponsor.

Experimental: Part 2: Cohort f - Participants of all age groups will receive daily dose of JNJ-53718678 oral solution or placebo, either in a qd or a bid regimen on Days 1 to 7.


Treatment: drugs: JNJ-53718678
JNJ-53718678 oral solution will be administered once or twice daily for 7 days.

Treatment: drugs: Placebo
Placebo oral solution will be administered once or twice daily for 7 days.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Maximum Observed Plasma Concentration (Cmax) of JNJ-53718678 - The Cmax is the maximum observed plasma concentration.</outcome>
      <timepoint>Days 1, 2 and 3</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Trough Plasma Concentration (Ctrough) of JNJ-53718678 - The Ctrough is the plasma concentration before dosing or at the end of the dosing interval of any dose other than the first dose in a multiple dosing regimen.</outcome>
      <timepoint>Days 1, 2 and 3</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) - The AUCtau is the measure of the plasma drug concentration from time zero to end of dosing interval.</outcome>
      <timepoint>Days 1, 2 and 3</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Total Apparent Clearance (CL/F) of JNJ-53718678 - Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</outcome>
      <timepoint>Days 1, 2 and 3</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Apparent Volume of Distribution (Vd/F) of JNJ-53718678 - Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vd/F) is influenced by the fraction absorbed.</outcome>
      <timepoint>Days 1, 2 and 3</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of Participants With Adverse Events - An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.</outcome>
      <timepoint>Up to Follow-up (Day 28)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Area Under the Viral Load-time Curve (VL AUC) - VL will be determined by quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR) assay of nasal swabs. The VL AUC (copies. hour/ml) will be calculated based on the trapezoidal method.</outcome>
      <timepoint>Up to Follow-up (Day 28)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Amount of Viral Load Over Time - VL (copies/ml) at each assessment timepoint where a nasal sample is obtained.</outcome>
      <timepoint>Up to Follow-up (Day 28)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of viral particles at Peak Viral Load - Peak viral load (copies/ml) is a measure of the maximum number of viral particles present in nasal swabs.</outcome>
      <timepoint>Up to Follow-up (Day 28)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time To Peak Viral Load - Time (hours) to peak viral load will be reported.</outcome>
      <timepoint>Up to Follow-up (Day 28)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants Reaching Undetectability of virus Between First Administration of Study Drug and Day 28 - Non-detectability of virus in nasal swabs between first administration of study drug and Day 28 will be reported.</outcome>
      <timepoint>Day 1 to Day 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total Number of Respiratory Syncytial Virus (RSV) Hospitalization Days from Admission to Discharge - The total number of Respiratory Syncytial Virus (RSV) hospitalization days from admission to discharge will be reported.</outcome>
      <timepoint>Up to Follow-up (Day 28)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total RSV Hospitalization Days with Supplemental Oxygen Requirement - The total number of RSV Hospitalization Days with Supplemental Oxygen Requirement will be reported.</outcome>
      <timepoint>Up to Follow-up (Day 28)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The Number of days in Intensive care unit (ICU) due to RSV - The number of days stayed in ICU due to RSV will be reported.</outcome>
      <timepoint>Up to Follow-up (Day 28)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total Days of non-invasive ventilator support During RSV Hospitalization - The total number of days with non-invasive ventilator support during RSV hospitalization will be reported.</outcome>
      <timepoint>Up to Follow-up (Day 28)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total Days of Mechanical Ventilation During RSV Hospitalization - The total number of days with Mechanical Ventilation during RSV hospitalization will be reported.</outcome>
      <timepoint>Up to Follow-up (Day 28)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in Peripheral Capillary Oxygen Saturation (SpO2) - The Percentage of Peripheral Capillary Oxygen Saturation (SpO2) will be assessed by the investigator during hospitalisation.</outcome>
      <timepoint>Up to Follow-up (Day 28)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in Respiratory Rate - The Respiratory rate (number of breaths per minute) will be assessed by the investigator and caregiver during hospitalisation.</outcome>
      <timepoint>Up to Follow-up (Day 28)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in Body Temperature - The body temperature (degrees Celcius) will be assessed by the investigator and caregiver during hospitalisation.</outcome>
      <timepoint>Up to Follow-up (Day 28)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical Symptom Score - The clinical symptom score will be assessed by the investigator (Clinician Outcome Assessment) and caregiver symptom Diary for each symptom. Clinical Symptom score ranges from 0 (best) to 4 (worst).</outcome>
      <timepoint>Up to Follow-up (Day 28)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Participant has presented at the hospital for suspected Respiratory Syncytial Virus
             (RSV) infection within 72 hours prior to Screening completion

          -  Participant has been hospitalized for this suspected RSV infection

          -  Participant has been diagnosed with RSV infection using a polymerase chain reaction
             (PCR)-based assay, preferably commercially available locally

          -  Participant was born after a normal term pregnancy (greater than or equal to 37 weeks
             and 0 days)

          -  A legally acceptable representative of the participant must sign an Informed consent
             form (ICF) indicating that he or she understands the purpose of and procedures
             required for the study, are willing for their child to participate in the study, are
             willing for their child to remain in the hospital for the first 3 days of dosing (even
             if not clinically indicated), and are willing/able to adhere to the prohibitions and
             restrictions specified in the protocol and study procedures</inclusivecriteria>
    <inclusiveminage>1</inclusiveminage>
    <inclusiveminagetype>Month</inclusiveminagetype>
    <inclusivemaxage>24</inclusivemaxage>
    <inclusivemaxagetype>Months</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Participant who had major surgery within the 28 days prior to randomization or planned
             major surgery through the course of the study

          -  Participant has major congenital anomalies or known cytogenetic disorders

          -  Participant has known or suspected immunodeficiency, such as known human
             immunodeficiency virus (HIV) infection

          -  Participant has known or suspected hepatitis B or C infection

          -  Participant is upon current admission initially hospitalized in the Intensive care
             unit (ICU) and/or in need of invasive endotracheal mechanical ventilation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>4/12/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>96</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Suspended</recruitmentstatus>
    <anticipatedlastvisitdate>30/11/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Geelong</hospital>
    <hospital> - Hobart</hospital>
    <hospital> - Westmead</hospital>
    <postcode> - Geelong</postcode>
    <postcode> - Hobart</postcode>
    <postcode> - Westmead</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Bahía Blanca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>City Of Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Córdoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Anderlecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Charleroi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Lier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Curitiba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Porto Alegre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Ribeirao Preto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio De Janeiro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>München</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Hoofddorp</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Cebu City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Manila City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Almeria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Esplugues De Llobregat</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Getafe</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Malaga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Santiago De Compostela</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Göteborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Linköping</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Lund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Malmö</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Janssen Sciences Ireland UC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate pharmacokinetics, safety, tolerability, antiviral
      activity, and impact on the clinical course of Respiratory Syncytial Virus (RSV) infection
      after multiple oral doses of JNJ-53718678 at different doses and/or dosing regimens in
      infants (greater than [&gt;] 1 month to less than or equal to [&lt;=] 24 months of age) who are
      hospitalized with RSV infection.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02593851</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Janssen Sciences Ireland UC Clinical Trial</name>
      <address>Janssen Sciences Ireland UC</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>